<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yang ZL</submitter><funding>National Key Basic Research Program</funding><funding>National Natural Science Foundation of China</funding><funding>Natural Science Foundation of Jiangsu Province</funding><pagination>1700847</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5980201</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(5)</volume><pubmed_abstract>Oxygen (O2) plays a critical role during photodynamic therapy (PDT), however, hypoxia is quite common in most solid tumors, which limits the PDT efficacy and promotes the tumor aggression. Here, a safe and multifunctional oxygen-evolving nanoplatform is costructured to overcome this problem. It is composed of a prussian blue (PB) core and chlorin e6 (Ce6) anchored periodic mesoporous organosilica (PMO) shell (denoted as PB@PMO-Ce6). In the highly integrated nanoplatform, the PB with catalase-like activity can catalyze hydrogen peroxide to generate O2, and the Ce6 transform the O2 to generate more reactive oxygen species (ROS) upon laser irradiation for PDT. This PB@PMO-Ce6 nanoplatform presents well-defined core-shell structure, uniform diameter (105 ± 12 nm), and high biocompatibility. This study confirms that the PB@PMO-Ce6 nanoplatform can generate more ROS to enhance PDT than free Ce6 in cellular level (p &lt; 0.001). In vivo, the singlet oxygen sensor green staining, tumor volume of tumor-bearing mice, and histopathological analysis demonstrate that this oxygen-evolving nanoplatform can elevate singlet oxygen to effectively inhibit tumor growth without obvious damage to major organs. The preliminary results from this study indicate the potential of biocompatible PB@PMO-Ce6 nanoplatform to elevate O2 and ROS for improving PDT efficacy.</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>Oxygen-Evolving Mesoporous Organosilica Coated Prussian Blue Nanoplatform for Highly Efficient Photodynamic Therapy of Tumors.</pubmed_title><pmcid>PMC5980201</pmcid><funding_grant_id>2014CB744504</funding_grant_id><funding_grant_id>81501538</funding_grant_id><funding_grant_id>81230032</funding_grant_id><funding_grant_id>81322020</funding_grant_id><funding_grant_id>BK20160017</funding_grant_id><funding_grant_id>2014CB744501</funding_grant_id><funding_grant_id>81530054</funding_grant_id><pubmed_authors>Teng ZG</pubmed_authors><pubmed_authors>Zhang LJ</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Zhang YL</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Tian W</pubmed_authors><pubmed_authors>Wang SJ</pubmed_authors><pubmed_authors>Tian Y</pubmed_authors><pubmed_authors>Tang YX</pubmed_authors><pubmed_authors>Lu GM</pubmed_authors><pubmed_authors>Ni QQ</pubmed_authors><pubmed_authors>Yang ZL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Oxygen-Evolving Mesoporous Organosilica Coated Prussian Blue Nanoplatform for Highly Efficient Photodynamic Therapy of Tumors.</name><description>Oxygen (O2) plays a critical role during photodynamic therapy (PDT), however, hypoxia is quite common in most solid tumors, which limits the PDT efficacy and promotes the tumor aggression. Here, a safe and multifunctional oxygen-evolving nanoplatform is costructured to overcome this problem. It is composed of a prussian blue (PB) core and chlorin e6 (Ce6) anchored periodic mesoporous organosilica (PMO) shell (denoted as PB@PMO-Ce6). In the highly integrated nanoplatform, the PB with catalase-like activity can catalyze hydrogen peroxide to generate O2, and the Ce6 transform the O2 to generate more reactive oxygen species (ROS) upon laser irradiation for PDT. This PB@PMO-Ce6 nanoplatform presents well-defined core-shell structure, uniform diameter (105 ± 12 nm), and high biocompatibility. This study confirms that the PB@PMO-Ce6 nanoplatform can generate more ROS to enhance PDT than free Ce6 in cellular level (p &lt; 0.001). In vivo, the singlet oxygen sensor green staining, tumor volume of tumor-bearing mice, and histopathological analysis demonstrate that this oxygen-evolving nanoplatform can elevate singlet oxygen to effectively inhibit tumor growth without obvious damage to major organs. The preliminary results from this study indicate the potential of biocompatible PB@PMO-Ce6 nanoplatform to elevate O2 and ROS for improving PDT efficacy.</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 May</publication><modification>2025-04-26T08:29:34.78Z</modification><creation>2019-03-26T23:40:35Z</creation></dates><accession>S-EPMC5980201</accession><cross_references><pubmed>29876209</pubmed><doi>10.1002/advs.201700847</doi></cross_references></HashMap>